SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

ELTP RSS Feed
Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: Drugdoctor, dr_lowenstein, lasers, NASDAQ2020, IB_, Chasing
Search This Board: 
Last Post: 9/26/2017 12:21:48 AM - Followers: 834 - Board type: Free - Posts Today: 1

Elite Pharmaceuticals, Inc. (ELTP)

 
About Elite Pharmaceuticals
 
Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology. 
 
Located in Northvale, New Jersey, Elite operates a 55,000 square foot campus under Current Good Manufacturing Practice (“cGMP”) and is a United States Drug Enforcement Agency (“DEA”) registered facility for research, development, manufacturing and packaging of pharmaceutical products.
 
More information including Elite’s proprietary Abuse Resistant Technology can be found at http://www.elitepharma.com
 


About Elite's Abuse Deterrent Technology

Elite's abuse deterrent products utilize the Company's proprietary pharmacological abuse deterrent technology. Elite's abuse deterrent technology is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist. Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers.
 
Elite continues to expands the intellectual property for the Company's opioid abuse deterrent technology. Elite now has four US patents, one European patent, and two Canadian patents issued in this area with additional patents pending in the U.S., Canada and Europe.
 
Products & Pipeline
 
Screen%20Shot%202017-05-28%20at%2011.53.29%20AM.png
 
Elite’s principle product is SequestOx, an immediate-release oxycodone with sequestered naltrexone abuse-deterrent opioid product for the management of moderate to severe acute pain. Additional products include bariatric, cardiovascular, antihistamine, skeletal muscle relaxants, antipsychotic, tricyclic antidepressant, along with a number of approved products pending manufacturing site transfer.
 
Elite owns generic and OTC products which have been licensed to TAGI Pharma, Epic Pharma, Dr. Reddy's Laboratories and Valeant Pharmaceuticals International. Additional information regarding Elite’s wholly owned products, partnerships, and contract manufacturing can be found at  http://www.elitepharma.com/products
 
The list of pipeline products can be found at http://www.elitepharma.com/pipeline-generics
 
Leadership
 
Nasrat Hakim, Chairman, President & Chief Executive Officer
 
Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership.  Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company. 

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.
 

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222
Email: 
dianne@elitepharma.com

Corporate Headquarters
165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755


 

Miscellaneous Links:
 
Elite Pharmaceuticals News
http://ir.elitepharma.com/press_releases
 
SEC Filings
http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001053369&owner=include

FDA website
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails

Clinical Trials.Gov
https://www.clinicaltrials.gov/
 
Yahoo Finance
https://finance.yahoo.com/quote/ELTP/?p=ELTP
 
Seeking Alpha
https://seekingalpha.com/symbol/ELTP
 

ELTP Daily Chart
    


SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
ELTP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ELTP News: Current Report Filing (8-k) 09/07/2017 04:32:57 PM
ELTP News: Current Report Filing (8-k) 08/09/2017 05:01:18 PM
ELTP News: Quarterly Report (10-q) 08/09/2017 04:30:20 PM
ELTP News: Current Report Filing (8-k) 07/28/2017 12:59:52 PM
ELTP News: Confidential Treatment Order (ct Order) 07/12/2017 05:00:02 PM
PostSubject
#271297  Sticky Note Elite Pharmaceuticals Files ANDA for Oxycodone Hydrochloride Extended Release SCHH 09/20/17 08:41:36 AM
#271038  Sticky Note Elite Pharma at Pain Week 2017 NASDAQ2020 09/17/17 04:03:01 PM
#260714  Sticky Note Uh, no. WeeZuhl 06/13/17 02:21:47 PM
#234937  Sticky Note THIS IS WHAT YOU NEED TO KNOW BEFORE Couch 11/30/16 03:04:07 PM
#189564  Sticky Note $ELTP SequestOx and ADF Patents lasers 03/18/16 04:29:26 AM
#185967  Sticky Note The only topic here is ELTP. IH Admin [Dan] 02/23/16 09:32:46 PM
#272019   I would say the lotto has better odds newguy11 09/26/17 12:21:48 AM
#272017   I was told at 57¢ that 26.5¢ was John_Langston 09/25/17 10:06:58 PM
#272015   That couldn't be. there was no way the John_Langston 09/25/17 09:51:28 PM
#272013   Not in 30 years for Elite. lol John_Langston 09/25/17 09:47:28 PM
#272011   I was told sub penny was coming - Couch 09/25/17 09:45:37 PM
#272010   No one can't short an OTC POS like John_Langston 09/25/17 09:43:16 PM
#272009   Still no $2 dollar shares just the PPS John_Langston 09/25/17 09:40:35 PM
#272008   I was told at 97¢ that ELTP was John_Langston 09/25/17 09:38:25 PM
#272007   Everyone should buy all they can below 10¢. lol John_Langston 09/25/17 09:33:51 PM
#272006   Elite's Multi-Billion Dollar Pipeline: NASDAQ2020 09/25/17 09:18:28 PM
#272005   LMFAO literally! So the PPS hit .12 and Couch 09/25/17 09:14:32 PM
#272004   LMFAO!! Gee and STILL no "SOON" 26.5¢ shares John_Langston 09/25/17 09:12:42 PM
#272003   SELERS DRYED OUT NO SELERS NEXT $2 DOLLARS John_Langston 09/25/17 09:07:47 PM
#272002   20 Pathways to DollarLand NASDAQ2020 09/25/17 09:06:56 PM
#272000   Gee you mean the FDA doesn't just approve Couch 09/25/17 08:34:29 PM
#271999   LMAO- and at .06 cents I said a Couch 09/25/17 08:30:30 PM
#271998   Gee and here I was told a 10 Couch 09/25/17 08:28:38 PM
#271997   I agree; still no "SOON" .02's = lol Couch 09/25/17 08:24:49 PM
#271996   Gee and here I was told the same Couch 09/25/17 08:22:10 PM
#271995   SELERS DRYED OUT NO SELERS NEXT 15 CENT COMING doczugunda 09/25/17 08:20:09 PM
#271994   LMFAO!! Gee and STILL no "SOON" .02's = Couch 09/25/17 08:19:36 PM
#271993   Absolutely not you were totally incorrect you don’t rocioyogi 09/25/17 08:19:14 PM
#271992   MM DOING GOOD JOB KEEPING PRICE 10 CENT doczugunda 09/25/17 08:19:11 PM
#271990   nobody is willing to sell at these prices John_Langston 09/25/17 07:45:56 PM
#271989   By are you can go that’s right you rocioyogi 09/25/17 07:43:31 PM
#271988   Nobody is selling at these prices not even John_Langston 09/25/17 07:35:33 PM
#271987   LOL, place a market order for 50 million John_Langston 09/25/17 07:32:46 PM
#271986   the recent generic filings are worth John_Langston 09/25/17 07:22:01 PM
#271985   LMAO - and 2 plus years later and John_Langston 09/25/17 07:19:39 PM
#271984   Another 10 bagger is coming from the current PPS John_Langston 09/25/17 07:17:44 PM
#271983   John_Langston YOUR RIGHT MM DOING GOOD JOB KEEPING John_Langston 09/25/17 07:15:43 PM
#271982   Elite would never have enough money for a John_Langston 09/25/17 06:54:00 PM
#271981   Indeed!! Elite is hemorrhaging cash!!! Big Trouble!! John_Langston 09/25/17 06:51:14 PM
#271980   They are holding for sub-penny shares so they John_Langston 09/25/17 06:49:27 PM
#271979   Gee must be why the PPS moved from John_Langston 09/25/17 06:47:49 PM
#271978   That won't be a problem when they get John_Langston 09/25/17 06:46:06 PM
#271977   FDA OR BIG PHARMA? WHO IS BETTER AT John_Langston 09/25/17 06:44:40 PM
#271976   frustrating man! John_Langston 09/25/17 06:34:38 PM
#271975   I have been saying the same thing since John_Langston 09/25/17 06:32:19 PM
#271974   I heard the same BS at 6.8¢. John_Langston 09/25/17 06:29:07 PM
#271973   at least with the low vol. no one John_Langston 09/25/17 06:28:07 PM
#271972   So why hasn't nasRAT done a PR to John_Langston 09/25/17 06:24:54 PM
#271971   Someone(s) bought 96,421 shares today. Big money big money John_Langston 09/25/17 06:23:13 PM
#271970   Nobody is selling at these prices not even rocioyogi 09/25/17 06:23:01 PM
#271969   nobody is selling cheep John_Langston 09/25/17 06:19:38 PM
#271968   No matter how much you want to buy rocioyogi 09/25/17 06:17:22 PM
#271967   LOL, I love it. John_Langston 09/25/17 06:16:42 PM
#271966   Does lack of volume mean nobody is selling John_Langston 09/25/17 06:11:59 PM
#271965   207,079 traded all day. John_Langston 09/25/17 06:11:04 PM
#271964   Explain why it's taking so long John_Langston 09/25/17 06:10:03 PM
PostSubject